-
1 Comment
Metropolis Healthcare Limited is currently in a long term uptrend where the price is trading 35.2% above its 200 day moving average.
From a valuation standpoint, the stock is 152.7% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 12.1.
Metropolis Healthcare Limited's total revenue rose by 23.3% to $3B since the same quarter in the previous year.
Its net income has increased by 39.2% to $586M since the same quarter in the previous year.
Finally, its free cash flow fell by 8.8% to $935M since the same quarter in the previous year.
Based on the above factors, Metropolis Healthcare Limited gets an overall score of 3/5.
Sector | Healthcare |
---|---|
Industry | Diagnostics & Research |
Exchange | NSE |
CurrencyCode | INR |
ISIN | INE112L01020 |
Market Cap | 109B |
---|---|
PE Ratio | 71.26 |
Target Price | 2144.5264 |
Beta | 0.09 |
Dividend Yield | None |
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for METROPOLIS.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025